Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous IL-12/multi-targeted primed T cells RPTR 168

A preparation of genetically modified, multi-antigen-targeted autologous T lymphocytes, tethered with the human immunostimulatory cytokine interleukin-12 (IL-12), with potential immunostimulating and antineoplastic activities. RPTR 168 is prepared from monocyte-derived dendritic cells (moDCs) that are pulsed with five tumor-associated antigens (TAAs) to expand cytotoxic T lymphocytes (CTLs) that are subsequently loaded with IL-12. Upon administration, the autologous IL-12/multi-targeted primed T cells RPTR 168 specifically target tumor cells expressing the five TAAs, which lead to a specific cytotoxic T-lymphocyte (CTL)-mediated killing of these tumor cells. In addition, IL-12 expression activates the immune system by promoting the secretion of interferon-gamma (IFN-g), activating natural killer cells (NKs), and inducing CTL responses, which may further increase tumor cell death and decrease tumor cell proliferation.
Synonym:autologous IL-12-expressing MTC RPTR 168
autologous IL-12/multi-targeted primed T lymphocytes RPTR 168
PRIME IL-12
Code name:RPTR 168
RPTR-168
RPTR168
Search NCI's Drug Dictionary